Deep dive · Oct 17, 2026 · updated Oct 18, 2026

Prescription stock finder for ADHD meds: what to build first

A builder's deep dive on a 4.15-Hotness idea: the r/ADHD evidence, why price apps miss it, an $864K obtainable market, and a four-week MVP scope.

Some products are hard to build because the code is hard. This one is hard because the data is hard, and that is exactly why it is still open.

People with ADHD who take stimulant medication describe the same loop: the prescription is written, the first pharmacy does not have it, and the next step is to phone store after store until one does. That is a sustained executive-function task, imposed on the people whose condition makes it hardest. A public thread in r/ADHD titled “For anyone who dreads calling around to find your…” drew 637 upvotes and 71 comments between September 14 and October 14, 2026.

This post is the builder’s view of the Prescription Stock Finder for ADHD Meds: what the evidence says, what the current options miss, how large the market could be, and the smallest version worth shipping.

The evidence: one thread, a loud signal

Our catalog ranks ideas by Hotness, a 1 to 5 score that mixes pain, willingness to pay, public demand, the gap left by current tools, build effort and how fresh the evidence is. This idea scores 4.15, which puts it in the scorching tier. The signal breakdown explains the score better than the headline number does:

Read the table as a trade. Pain, demand and recency are maxed out, so you do not need to manufacture a need. The weak spots are ease of build and willingness to pay, which tells you where the risk lives: getting trustworthy availability data, and charging enough to keep it fresh.

We quote only the thread title. We do not claim to know what every commenter said, and neither should your landing page. The title and the link are the evidence; the engagement numbers are the strength of it.

What people use today, and why it falls short

Two alternatives come up in our data.

Calling pharmacies manually. It works, eventually, and it is exactly the task the user wants to stop doing. It does not scale, it repeats every month, and the answer is only true for that day.

GoodRx. It answers a different question. It shows prices, not stock. A cheaper price at a pharmacy that does not have the medication does not help someone whose problem is finding it at all.

That is the whole gap in one sentence: price tools exist, stock tools do not. A builder does not need to beat GoodRx at pricing. You need to answer “who has it right now” well enough that people stop dialing.

How big it could get

Our market estimate is deliberately plain about its inputs. It starts from CDC MMWR (Oct 2024): 15.5M adults, 33.4% of them on stimulants, and 71.5% of those reporting trouble filling a prescription. That gives a base of 3,700,000 US adults on stimulants who could not fill a prescription in 2023.

The revenue line assumes $3.99 a month for alerts, about $48 a year per adult, and that 25% of the base is reachable through smartphones and ADHD communities. In plain words: 18,000 adults at $4 a month is $864K in annual recurring revenue. Our confidence in the estimate is medium.

For a solo founder or a small team, that SOM is the useful number. It is not a venture-scale market on its own, but it is a real one, and the price band (under $10 a month) matches how the audience already thinks about utility apps.

The MVP: four weeks, one job

The scope we publish on the idea page is narrow on purpose. The goal is one job: find which nearby pharmacy actually has the prescription in stock, without calling ten stores.

Week 1 is the whole risk

The hard part is not the interface. It is where availability comes from. The idea data flags this directly: it needs integrations or data deals. Before you write the alert logic, decide which of these you are betting on:

• Partnerships or feeds from chains or pharmacy software vendors. Strongest data, slowest to get.
• Crowdsourced reports, where users who just found the medication mark it as in stock. The tag list for this idea includes crowdsourced data for a reason: it can ship in week 1.
• A hybrid, where crowdsourced reports bootstrap coverage and partnerships replace them where they exist.

A crowdsourced first version is honest about what it is: “someone found it here today”, with a timestamp. It should never present itself as a pharmacy or promise a fill. Controlled medication is a sensitive category, and trust is the product.

Where AI fits

AI is an assist here, not the core. The core job works without a model. Useful assists are small: summarizing recent reports per pharmacy, or flagging stale entries. If the AI fails, the list of fresh reports must still be usable.

What to leave out

Leave out price comparison, refill reminders, telehealth and anything that turns this into a general pharmacy app. Each one is reasonable on its own, and each one delays the only thing users asked for.

Pricing and the freemium line

The model in our data is freemium with a price point under $10 a month. A clean split for this product:

• Free: search and see recent reports near you.
• Paid ($3.99 a month in our estimate): alerts when your specific medication and dose is reported in stock near you.

Alerts are the natural paywall because they save the most effort and cost the most to run. Willingness to pay scores 3 out of 5, so keep the price low and make the free tier useful enough that people contribute reports.

What the PRD gives you

The idea page is free: the thread, the competitors, the gap, the market estimate and the MVP scope above. The PRD is the paid part. It is an agent starter prompt written for this exact product, covering the product, the problem, the users and the scope, so a coding agent starts from the decisions in this post instead of a blank page. It costs one credit ($9.99).

If you would rather run this as a hands-on service before writing software, the sister site covers that angle: a business plan and growth playbook for a prescription stock finder.

Key takeaways

• The demand is public and recent: 637 upvotes and 71 comments on one r/ADHD thread in our Sep 14 to Oct 14, 2026 window.
• The gap is specific: price tools exist, stock tools do not. GoodRx shows prices, not availability.
• Our estimate, based on CDC MMWR (Oct 2024), puts the obtainable market at about $864K a year: 18,000 adults at $4 a month.
• The risk is data, not code. Decide in week 1 between partnerships, crowdsourced reports or a hybrid.
• Ship a phone app with alerts in about four weeks, keep AI as an assist, and leave everything else out of v1.

All posts